Tirzepatide

Tirzepatide

Tirzepatide is a synthetic 39-amino acid dual agonist peptide targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Originally developed as a novel approach to metabolic disease research, tirzepatide has attracted significant scientific interest for its dual incretin mechanism, which distinguishes it from single-receptor GLP-1 agonists. It is supplied here as a lyophilised research compound for in vitro and preclinical investigation.

Mechanism of Action

Tirzepatide acts as a co-agonist at GIP (GIPR) and GLP-1 (GLP-1R) receptors, both of which are G-protein-coupled receptors that signal via cAMP elevation. GLP-1R activation enhances glucose-dependent insulin secretion and suppresses glucagon release, while GIPR activation contributes additional insulinotropic and potentially adipose-regulatory effects. The dual agonism is hypothesised to produce synergistic metabolic effects beyond those achievable with GLP-1 monotherapy, making tirzepatide a key subject in obesity, insulin resistance, and metabolic syndrome research.

Research Applications

• Dual GIP/GLP-1 receptor pharmacology studies
• Insulin secretion and glucose homeostasis modelling
• Obesity and adipose tissue metabolism research
• Incretin biology and pancreatic beta-cell function investigation
• Metabolic syndrome and insulin resistance preclinical models

Specifications

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.5 g/mol
• CAS Number: 2023788-19-2
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.